Fas expression by tumor stroma is required for cancer eradication

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 6, 2013, Pages 2276-2281

  Listopad, Joanna J ^a,b   Kammertoens, Thomas ^a,b   Anders, Kathleen ^a   Silkenstedt, Bjoern ^b   Willimsky, Gerald ^a,b   Schmidt, Karin ^b   Kuehl, Anja A ^b   Loddenkemper, Christoph ^c   Blankenstein, Thomas ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Charité Campus Benjamin Franklin Medical Center   (Germany)

Author keywords

Immune escape; T cell therapy

Indexed keywords

FAS ANTIGEN; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CONTROL; CD8+ T LYMPHOCYTE; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN VIRUS; TUMOR REJECTION;

ANIMALS; ANTIGENS, CD95; CELL LINE, TUMOR; FAS LIGAND PROTEIN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; NEOPLASMS; PORE FORMING CYTOTOXIC PROTEINS; RECEPTORS, INTERFERON; STROMAL CELLS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84873472673     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1218295110     Document Type: Article

References (35)

1. Dudley ME, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346-2357.
2. Zippelius A, et al. (2004) Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance. Cancer Res 64(8):2865-2873.
3. + T cells in metastases from melanoma patients. J Clin Invest 121(6):2350-2360.
4. Wen FT, Thisted RA, Rowley DA, Schreiber H (2012) A systemic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology 1:172-178.
5. Schreiber K, Rowley DA, Riethmüller G, Schreiber H (2006) Cancer immunotherapy and preclinical studies: Why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am 20(3):567-584.
6. Kast WM, et al. (1989) Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59(4):603-614.
7. Spiotto MT, Rowley DA, Schreiber H (2004) Bystander elimination of antigen loss variants in established tumors. Nat Med 10(3):294-298.
8. Anders K, et al. (2011) Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell 20(6): 755-767.
9. Zhang B, Karrison T, Rowley DA, Schreiber H (2008) IFN-gamma-and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 118(4):1398-1404.
10. Qin Z, Blankenstein T (2000) CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNgamma receptor expression by nonhematopoietic cells. Immunity 12(6):677-686.
11. Qin Z, et al. (2003) A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 63(14):4095-4100.
12. Schüler T, Blankenstein T (2003) Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J Immunol 170(9): 4427-4431.
13. Weinstein IB (2002) Cancer. Addiction to oncogenes-The Achilles heal of cancer. Science 297(5578):63-64.
14. Staveley-O'Carroll K, et al. (2003) In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol 171(2):697-707.
15. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89(16): 7491-7495.
16. Willimsky G, Blankenstein T (2005) Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437(7055):141-146.
17. Briesemeister D, et al. (2011) Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis. Int J Cancer 128(2):371-378.
18. Hollenbaugh JA, Dutton RW(2006) IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol 177(5): 3004-3011.
19. Restifo NP, et al. (1996) Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88(2):100-108.
20. Huss WJ, et al. (2007) Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 9(11):938-950.
21. Urban JL, Schreiber H (1992) Tumor antigens. Annu Rev Immunol 10:617-644.
22. Spiotto MT, Schreiber H (2005) Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun 5:8.
23. Qin Z, Blankenstein T (2004) A cancer immunosurveillance controversy. Nat Immunol 5(1):3-4, author reply 4-5.
24. Dobrzanski MJ, Reome JB, Hollenbaugh JA, Hylind JC, Dutton RW (2004) Effector cellderived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases. Cancer Res 64(1):406-414.
25. Tanaka Y, Tevethia SS (1988) In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones. J Immunol 140(12):4348-4354.
26. Mackensen A, et al. (2006) Phase I study of adoptive T-cell therapy using antigenspecific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24(31):5060-5069.
27. Janin A, et al. (2002) CD95 engagement induces disseminated endothelial cell apoptosis in vivo: Immunopathologic implications. Blood 99(8):2940-2947.
28. Stranges PB, et al. (2007) Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity 26(5):629-641.
29. Wynes MW, et al. (2011) Increased cell surface Fas expression is necessary and sufficient to sensitize lung fibroblasts to Fas ligation-induced apoptosis: Implications for fibroblast accumulation in idiopathic pulmonary fibrosis. J Immunol 187(1):527-537.
30. Wang R, Rogers AM, Ratliff TL, Russell JH (1996) CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors. J Immunol 157(7):2961-2968.
31. Wigginton JM, et al. (2001) IFN-β and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 108(1):51-62.
32. Shanker A, et al. (2009) Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res 69(16):6615-6623.
33. Chen L, et al. (2010) CD95 promotes tumour growth. Nature 465(7297):492-496.
34. Mackall CL, et al. (1995) Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 332(3):143-149.
35. Flood PM, Urban JL, Kripke ML, Schreiber H (1981) Loss of tumor-specific and idiotype-specific immunity with age. J Exp Med 154(2):275-290.